p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer

Administration of the microtubule inhibitor docetaxel is a common treatment for metastatic castration-resistant prostate cancer (mCRPC) and results in prolonged patient overall survival. Usually, after a short period of time chemotherapy resistance emerges and there is urgent need to find new therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruber, Martina, Ferrone, Lavinia, Puhr, Martin, Santer, Frédéric R, Furlan, Tobias, Eder, Iris E, Sampson, Natalie, Schäfer, Georg, Handle, Florian, Culig, Zoran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040497/
https://www.ncbi.nlm.nih.gov/pubmed/31951590
http://dx.doi.org/10.1530/ERC-19-0488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040497/
https://www.ncbi.nlm.nih.gov/pubmed/31951590
http://dx.doi.org/10.1530/ERC-19-0488

Ejemplares similares